Loading stock data…
Arcutis Biotherapeutics (ARQT)
$27.00+0.31 (+1.16%)
Pre-Market$27.20+0.20 (+0.74%)· Last close Jun 26
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcutis Biotherapeutics, Inc. in the Healthcare sector is trading at $27.00 with a market capitalization of $3.2B. Wall Street consensus targets $34.62 (8 analysts), implying a +28.2% move over the next 12 months. The stock is currently 15% below its 52-week high of $31.77, remaining 11.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +28.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105.40M↓ | $129.50M↑ | $99.22M↑ | $81.50M↑ | $65.85M |
| Gross Profit | $95.61M↓ | $117.81M↑ | $90.53M↑ | $74.01M↑ | $57.02M |
| Operating Income | -$9.09M↓ | $18.39M↑ | $8.53M↑ | -$14.61M↑ | -$24.53M |
| Net Income | -$11.29M↓ | $17.39M↑ | $7.41M↑ | -$15.89M↑ | -$25.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.25%
Volume
Today's trading volume
3.71M
Recent News
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%
This dermatology-focused biotech, known for its topical therapies, reported a notable insider sale amid strong one-year stock gains.
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?
In early June 2026, Arcutis Biotherapeutics reported that a Genital Psoriasis Wellness Consortium manuscript, supported by the company, was published in the American Journal of Clinical Dermatology, offering practical, consensus-based guidance for recognizing, diagnosing, and managing genital psoriasis across pediatric, adult, and older patients. This work highlights Arcutis’s broader effort to improve care in sensitive dermatologic conditions and promote non-steroidal options where...
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
Arcutis Biotherapeutics (NASDAQ:ARQT) executives said ZORYVE continues to post strong growth and outlined several regulatory and clinical catalysts expected over the next year, while emphasizing that the company has reached a self-sustaining financial position. Frank, Arcutis’ CEO, said the company
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion
In early May 2026, Arcutis Biotherapeutics reported first-quarter revenue of US$105.4 million, reduced its net loss to US$11.3 million, and reaffirmed full-year 2026 net product revenue guidance of US$480 million to US$495 million. The company also filed an sNDA to extend ZORYVE cream 0.05% to infants as young as 3 months with mild to moderate atopic dermatitis, potentially widening its addressable pediatric market with a steroid-free option in a segment that currently has only one other...
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Arcutis Biotherapeutics, Inc.'s Q1 2026 earnings call